4//SEC Filing
Tarriff Scott 4
Accession 0001209191-23-052030
CIK 0000827871other
Filed
Oct 3, 8:00 PM ET
Accepted
Oct 4, 5:07 PM ET
Size
10.1 KB
Accession
0001209191-23-052030
Insider Transaction Report
Form 4
Tarriff Scott
DirectorPresident and CEO
Transactions
- Sale
Common Stock
2023-10-02$15.23/sh−9,511$144,853→ 577,800 total - Sale
Common Stock
2023-10-03$14.41/sh−10,024$144,446→ 567,776 total - Sale
Common Stock
2023-10-03$15.11/sh−710$10,728→ 567,066 total
Holdings
- 992,623(indirect: By Trust)
Common Stock
Footnotes (5)
- [F1]These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 15, 2023.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.035 to $15.63 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4).
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.09 to $15.05 inclusive.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.09 to $15.18 inclusive.
- [F5]The shares are held by the Trust for the benefit of the Reporting Person's spouse and children. The Reporting Person does not have investment control over the shares held by the Trust and disclaims beneficial ownership of the shares, except to any pecuniary interest therein, if any.
Documents
Issuer
EAGLE PHARMACEUTICALS, INC.
CIK 0000827871
Entity typeother
Related Parties
1- filerCIK 0001469124
Filing Metadata
- Form type
- 4
- Filed
- Oct 3, 8:00 PM ET
- Accepted
- Oct 4, 5:07 PM ET
- Size
- 10.1 KB